Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: Comparison between subtype B and non-B genetic variants

Journal of Medical Virology

Volumn 84, Issue 4, 2012, Pages 551-554

  Pereira Vaz, João ^a   Duque, Vitor ^a   Pereira, Branca ^a   Mota, Vanda ^a   Morais, Célia ^a   Saraiva da Cunha, José ^a   Meliço Silvestre, António ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Antiviral therapy; Etravirine; HIV 1; Resistance

Indexed keywords

EFAVIRENZ; ETRAVIRINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ARTICLE; FOLLOW UP; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PORTUGAL; RETROSPECTIVE STUDY; STRUCTURAL GENE; VIRUS STRAIN;

ANTI-HIV AGENTS; BENZOXAZINES; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTANT PROTEINS; MUTATION, MISSENSE; PORTUGAL; PREVALENCE; PYRIDAZINES; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84856945777     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23232     Document Type: Article

References (17)

1. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, de Béthune MP. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 48: 4680- 4686.
2. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Loque K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 75: 4999- 5008.
3. Beheydt G, Vercauteren J, Levy I, Rudich H, Ram D, Carvalho AP, Van Laethem K, Vandamme AM, Camacho R, Grossman Z. 2010. Expected HIV-1 etravirine resistance after treatment failure with efavirenz and/or nevirapine. Antivir Ther 15: A65.
4. Benhamida J, Chappey C, Coakley E, Parkin NT. 2008. HIV-1 genotype algorithms for prediction of etravirine susceptibility: Novel mutations and weighting factors identified through correlations to phenotype. Antivir Ther 13: A142.
5. Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V. 2001. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 65: 445- 448.
6. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, Snoeck J, van Rensburg EJ, Wensing AM, van de Vijver DA, Boucher CA, Camacho R, Vandamme AM. 2005. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21: 3797- 3800.
7. Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. 2010. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 18: 156- 163.
8. Llibre JM, Santos JR, Puig T, Moltó J, Ruiz L, Paredes R, Clotet B. 2008. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicro Chemother 62: 909- 913.
9. Maïga AI, Descamps D, Morand-Joubert L, Malet I, Derache A, Cisse M, Koita V, Akonde A, Diarra B, Wirden M, Tounkara A, Verlinden Y, Katlama C, Costagliola D, Masquelier B, Calvez V, Marcelin AG. 2010. Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes. Antimicrob Agents Chemother 54: 728- 733.
10. Poveda E, Anta L, Blanco JL, Pérez-Elías MJ, García F, Leal M, Ribera E, Gutiérrez F, Soriano V, de Mendoza C. 2010. Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. AIDS 24: 469- 471.
11. Tambuyzer L, Azijn H, Rimsky LT, Vingerhoets J, Lecocq P, Kraus G, Picchio G, de Béthune MP. 2009. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir Ther 14: 103- 109.
12. Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D, Andries K, Pauwels R, de Béthune MP. 2005. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol 79: 12773- 12782.
13. Vingerhoets J, Azijn H, Tambuyzer L, Dierynck I, De Meyer S, Rimsky L, Nijs S, De Smedt G, de Béthune MP, Picchio G. 2010a. Short communication: Activity of etravirine on different HIV type 1 subtypes: In vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data. AIDS Res Hum Retroviruses 26: 621- 624.
14. Vingerhoets J, Buelens A, Peeters M, Picchio G, Tambuyzer L, Van Marck H, De Smedt G, Woodfall B, de Béthune MP. 2007. Impact of baseline NNRTI mutations on the virological response to TMC125 in the Phase III clinical trials DUET-1 and DUET-2. Antivir Ther 12: S34.
15. Vingerhoets J, Peeters M, Azijn H, Tambuyzer L, Hoogstoel A, Nijs S, de Béthune MP, Picchio G. 2008. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: Multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Antivir Ther 13: A26.
16. Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, de Béthune MP, De Smedt G, Woodfall B, Picchio G. 2010b. Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 24: 503- 514.
17. Vingerhoets J, Tambuyzer L, Azijn H, Nijs S, Picchio G. 2010c. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virological response to etravirine. Antivir Ther 15: A125.